Inhibition of TPL2 by interferon-α suppresses bladder cancer through activation of PDE4D

Inhibition of TPL2 by interferon-α suppresses bladder cancer through activation of PDE4D

Abstract Background Drugs that inhibit the MEK/ERK pathway have therapeutic benefit in bladder cancer treatment but responses vary with patients, for reasons that are still not very clear. Interferon-α (IFN-α) is also used as a therapeutic agent for bladder cancer treatment but the response rate is...

Full description

Bibliographic Details
Main Authors: Zhe Qiang, Zong-yuan Zhou, Ting Peng, Pu-zi Jiang, Nan Shi, Emmanuel Mfotie Njoya, Bahtigul Azimova, Wan-li Liu, Wei-hua Chen, Guo-lin Zhang, Fei Wang
Format: Article
Language:English
Published: BMC 2018-11-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Interferon
TPL2
PDE4D
cAMP
COX-2
Online Access:http://link.springer.com/article/10.1186/s13046-018-0971-4

Internet

http://link.springer.com/article/10.1186/s13046-018-0971-4

Similar Items